Your session is about to expire
← Back to Search
Behavioral Intervention
Mobile Text Messaging Support for Smoking Cessation
N/A
Waitlist Available
Led By Patricia Chalela, DrPH
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month and 3 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests Quitxt, a mobile program that sends supportive texts and chat messages to help young Latino adults quit smoking. The study focuses on this group because they have high smoking rates and face significant health risks. Quitxt aims to boost users' confidence and skills to quit smoking through culturally relevant messages. Text messaging programs on mobile phones have shown some promise in helping people quit smoking.
Who is the study for?
This study is for Latino young adults aged 18-29 who smoke at least one cigarette a day, want to quit smoking, own a cell phone with text and internet capabilities, and can provide follow-up data. They should not be in another cessation program or planning to move from the study area during the trial.
What is being tested?
The Quitxt research study tests a mobile text messaging intervention designed to help young Latino adults stop smoking. Participants are randomly assigned to receive either interactive Quitxt messages or standard texts with cessation content plus referral to an existing state health service program.
What are the potential side effects?
Since this trial involves text messaging interventions for smoking cessation rather than medication, there are no direct medical side effects. However, participants may experience typical nicotine withdrawal symptoms such as irritability, cravings, or difficulty concentrating.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month and 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month and 3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Smoking cessation
Secondary study objectives
Smoking cessation assessment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Usual careExperimental Treatment1 Intervention
Abbreviated text messaging with smoking cessation-related content and referral to the Texas Department of State Health Services (TDSHS) cessation program Yes Quit (www.yesquit.org) available to smokers seeking help quitting. The abbreviated text messaging will include general information on smoking harms and benefits of cessation, and baseline data collection and follow-up assessments.
Group II: Quitxt bilingual text messaging and chatExperimental Treatment1 Intervention
Culturally and linguistically tailored, bilingual text messaging or chat mobile app.
Our text messaging or chat intervention will include messaging options in which users can text or message a code when they are craving a cigarette or at risk of relapse and immediately receive text or social media messages to help them avoid smoking. The social media content also will include opportunities for users to repeatedly visit key content pages and receive immediate support when experiencing cravings, stress, bad mood, or when feeling at risk of smoking.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Interactive, bilingual, and culturally tailored mobile messaging interventions, like those studied in the Quitxt trial, work by providing personalized support and motivation to quit smoking. These messages often include educational content, coping strategies, and reminders to stay on track, which help patients manage cravings and reinforce their commitment to quit.
The cultural tailoring ensures that the content is relevant and resonates with the patient's background, increasing engagement and effectiveness. This matters for smoking cessation patients because it addresses both the psychological and social aspects of addiction, making it more likely for them to succeed in quitting smoking.
An international survey: Tobacco smoking cessation strategies within left ventricular assist device centers.Mobile phone-based messaging for tobacco cessation in low and middle-income countries: A systematic review.Culturally-tailored text-messaging intervention for smoking cessation in rural American Indian communities: Rationale, design, and methods.
An international survey: Tobacco smoking cessation strategies within left ventricular assist device centers.Mobile phone-based messaging for tobacco cessation in low and middle-income countries: A systematic review.Culturally-tailored text-messaging intervention for smoking cessation in rural American Indian communities: Rationale, design, and methods.
Find a Location
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
91,719 Total Patients Enrolled
Cancer Prevention Research Institute of TexasOTHER
54 Previous Clinical Trials
97,864 Total Patients Enrolled
The University of Texas at San AntonioOTHER
23 Previous Clinical Trials
6,354 Total Patients Enrolled
Patricia Chalela, DrPHPrincipal InvestigatorUniversity of Texas Health Science Center San Antonio
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not interested in quitting smoking.I am a Latino between 18 and 29 years old.I am unable to understand the consent information due to a condition.I want to quit smoking.
Research Study Groups:
This trial has the following groups:- Group 1: Quitxt bilingual text messaging and chat
- Group 2: Usual care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.